Please assess the completion status of the following clinical trial:

Trial Title: Human Albumin for the Treatment of Ascites in Patients With Hepatic Cirrhosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria~* Diagnosis of liver cirrhosis (based on clinical, laboratory, endoscopic and ultrasonographic features) and uncomplicated ascites according to the criteria of the International Ascites Club (1).~* Ongoing diuretic treatment with an anti-mineralocorticoid drug at a dose of 200 mg/day and furosemide of 25 mg/day, stable for at least 4 days prior enrollment, not inducing response (defined according to the criteria of the International Ascites Club as body weight reduction ≥ 800 grams in the 4 days prior enrollment). With this limitation, we aim to identify a fairly homogeneous population with a relatively advanced stage of the disease that will likely have more benefit from albumin administration, as also suggested by Gentilini at al. (17).~* Ongoing diuretic treatment with an anti-mineralocorticoid drug at a dose \> 200 mg/day and furosemide \> 25mg/day, independent of response to treatment.~* EGDS performed in the last 12 months, abdominal ultrasonography performed in the last 30 days, and laboratory tests required by the protocol in the last 7 days.~Exclusion criteria~* Age lower than 18 years~* No written informed consent~* Inability to follow written consent~* Established diagnosis of refractory ascites, as defined by the IAC (1)~* Need of 2 or more paracentesis during the last month~* Serum creatinine \> 1.5 mg/dl~* Organic nephropathy, as defined by the IAC (1)~* Hepatorenal syndrome type 1 in the last 15 days~* Gastrointestinal bleeding in the last 15 days~* Ongoing endoscopic eradication after a recent gastro-esophageal variceal bleeding~* Bacterial or fungal infection, including spontaneous bacterial peritonitis, in the last 7 days~* Hepatic encephalopathy grade III/IV~* Budd-Chiari Syndrome~* Patients with TIPS or other surgical porto-caval shunts~* Known and suspected active hepatocellular carcinoma or other malignancies~* Previous liver transplantation~* Ongoing alcohol abuse (patients should be abstinent for at least three months)~* Antiviral therapy for hepatitis B started in the last 6 months~* Heart failure~* Respiratory failure as defined as PO2 \<60 mmHg~* Known or suspected hypersensitivity to albumin~* Previous albumin administration given for the treatment of ascites in the last 30 days~* Patients enrolled in other clinical study for the treatment of ascites~* Use of experimental drugs for the last 2 months prior the inclusion in the present study~* Pregnancy and breast-feeding~* Females of child-bearing potential are excluded unless they meet one of the following criteria:~  * Post-menopausal for 6 months or more, and if post-menopausal for less than 2 years, a negative pregnancy test~ * Surgical sterilisation for more than one month duration and a negative pregnancy test~ * Intrauterine device in combination with a secondary barrier (e.g. diaphragm, condom or spermicide) and a negative pregnancy test

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Standard medical treatment plus albumin (Type: ACTIVE_COMPARATOR): The patients will receive standard medical treatment (diuretics) plus weekly albumin infusion
- Standard medical treatment (Type: OTHER): The patients will receive the standard medical treatment (diuretics), but non albumin for the therapy of ascites

Based on this trial design, predict the completion outcome and termination type (if applicable).